Biocompatibles' drug-leaching beads are good, but not great, in HCC
This article was originally published in Clinica
Executive Summary
UK firm Biocompatibles International is touting trial data which suggest that its drug-eluting bead (DEB) technology may be a better liver cancer therapy than embolisation.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.